Munchausen by proxy syndrome mimicking systemic autoinflammatory disease: case report and review of the literature

Helmut Wittkowski 1*, Claas Hinze 1, Sigrid Häfner-Harms 2, Vinzenz Oji 3, Katja Masjosthusmann 2, Martina Monninger 2, Ulrike Grenzbach 4 and Dirk Foell 1

Abstract

Background: Systemic autoinflammatory diseases (SAIDs) represent a growing number of monogenic, polygenic or multifactorial disorders that are often difficult to diagnose.

Case presentation: Here we report a patient who was initially erroneously diagnosed and treated for SAID. Symptoms consisted of recurrent fever, erythematous and/or blistering skin lesions, angioedema, susceptibility to bleeding, external ear infections and reversible anisocoria in the absence of laboratory evidence of systemic inflammation. After two and a half years of extensive diagnostic work-up and multiple empirical therapies, a final diagnosis of Munchausen by proxy syndrome (MBPS) was established.

Conclusions: The diagnosis of SAID needs to be carefully reassessed if measurable systemic inflammation is missing, and MBPS should be included in the differential diagnosis.

Keywords: Autoinflammation, Systemic autoinflammatory disease (SAID), Münchhausen by proxy syndrome (MBPS), Differential diagnosis

Background

Systemic autoinflammatory diseases (SAIDs) comprise of genetically defined conditions as well as disorders of unknown pathogenesis. Examples of monogenic SAIDs are Familial Mediterranean fever (FMF), cryopyrin associated periodic syndromes (CAPS), mevalonate kinase (MVK) deficiency and tumor necrosis factor receptor associated periodic syndrome (TRAPS). In cases where a specific diagnosis cannot be achieved, an undifferentiated SAID is assumed. In contrast to autoimmune diseases, SAIDs are driven by uncontrolled activation of the innate immune system [1, 2].

Typical clinical features include flares of recurrent inflammation, fever, skin rash, arthritis, serositis and organ involvement (e.g. skin, eyes, kidney). The clinical presentation of these disorders overlaps to a certain degree, complicating and delaying their diagnosis.

Moreover, co-factors responsible for genotype-phenotype variations are hard to identify, which can delay diagnosis further [3].

Munchausen by proxy syndrome (MBPS) in children, first described in 1977 by Meadow, refers to a fabricated or induced illness [4, 5]. Alternative terms for MBPS include factitious disorder by proxy or medical child abuse. Regardless of the nomenclature, MBPS is defined as harm carried out by a caregiver, usually the mother, where a medical condition is exaggerated, fabricated or induced [6]. Perpetrators often have medical knowledge or ties to the medical sector, may suffer from somatoform or factitious disease or personality disorders, or intend to gain social attention or raise money for personal use [5]. MBPS can be seen as a variant of battered child syndrome (BCS). While BCS is an important cause of overall paediatric morbidity and mortality with more than 650 thousand victims per year in the US, MBPS is...
actually a rare entity with an annual incidence of approximately 0.5/100,000 in children younger than 16 years, though it is likely to be underreported [5, 7]. The spectrum of systemic involvement with which MBPS may present is very broad and includes dermatologic, endocrine, gastrointestinal, hematologic, neurologic, metabolic, infectious or rheumatologic symptoms and fever.

Case presentation
We report the case of a 3 year old Caucasian boy who first developed erythematous patches distributed over the whole body at the age of 5 months (Fig. 1). A skin biopsy was performed, showing faint polymorphonuclear granulocytic infiltrates; a histopathologic diagnosis of probable autoinflammatory skin disease was made, which prompted further diagnostic evaluations into SAIDs (s. Table 1). At 8 months of age, macroscopic haematuria, bloody diarrhoea and epistaxis were reported by the mother. Shortly after, recurrent episodes of fever up to 39.5 °C, 1–3 days duration, were reported to be occurring every 2 weeks, accompanied by an increase in erythematous skin lesions. From the age of 12 months, ulcerative skin lesions developing on previously intact skin primarily on the extremities, a sudden-onset unilateral facial swelling and transient anisocoria were seen (Fig. 1). Deep skin defects developed after medical interventions such as bone marrow aspiration or immunizations, which were interpreted as representing a pathergy phenomenon. Subsequently, from the age of 18 months, palmoplantar bullous skin lesions occurred with rapid detachment of epidermal layers. One skin lesion on the foot healed with scar formation.

The boy was the youngest of several siblings of a family where both parents were part of the household and did not have connections to the health care sector, and who had no apparent psychiatric abnormalities.

A diagnosis of SAID was one of the first diagnoses suspected, and was first proposed by the dermatologists, as fever and skin symptoms are typical findings for these entities. However, extensive testing yielded negative results (Table 1). Autoimmune diseases and primary immunodeficiencies were ruled out by these investigations.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Fig_1}
\caption{Evolution of symptoms according to age of life (in months). 5 months: Initial symptoms were erythematous skin lesions distributed over the whole body (a-c). 8 months: Macrohaematuria, epistaxis and bloody diarrhoea were reported. 9 months: Fever episodes, every second week. 12 months: Deep skin lesions with excoriation and ulcerations (d). Anisocoria (g) and unilateral facial swelling with sudden occurrence and transient (h). 16 months: deep ulcerating or necrotizing skin lesions with impaired healing at bone marrow puncture site (e) or vaccination sites (f). 18 months: bullous skin lesions occurred with sudden detachment of epidermal layers with predominantly palmar and plantar localisation (i). Blisters healed without scarring usually after 2 weeks (j).}
\end{figure}
Due to suspecting a monogenic SAID like TRAPS or an undifferentiated SAID throughout the disease course, several treatments were implemented sequentially or in combination, including prednisolone up to 2 mg/kg/d, azathioprine (4 months of therapy), dapson (3 months of therapy), anakinra, ibuprofen and/or hydroxychloroquine. However, most of the signs and symptoms described above persisted or recurred during treatment.

Subsequently, clinical investigations shifted increasingly to the search for external and/or toxic factors. Contaminants in the household were considered and actively investigated, and screening for heavy metal poisoning was pursued. In total five hospital admissions for diagnostic purposes took place.

As the extensive work-up performed continued to yield only negative results, it became increasingly apparent that intrinsic disease was unlikely and MBPS was suspected. However, during a 3-week hospital stay with intensified surveillance, no maternal interference, that might explain the patient’s signs and symptoms was observed, symptoms remained the same. During this time two findings in particular aroused suspicion, (1) reversible unilateral (otherwise unexplainable) mydriasis, not reactive to topical application of pilocarpine 1% and (2) the sudden appearance of bullous skin lesions in previously intact skin. A North American expert panel on child abuse was consulted by telephone conference and it was felt that this case was highly suspicious for MBPS. Ultimately, both parents were confronted with the probable diagnosis with participation of the youth welfare service and an attending psychiatrist. As the mother was the person most consistently involved in the care of the child and was always present during hospital stays, we suspected her rather than the father to be the perpetrator. The mother and patient were separated immediately and the patient was admitted together with his father. Within 2 weeks all signs and symptoms of disease resolved.

In the meantime, the parents had contacted the police to report, that a crime had been committed by an unknown perpetrator. After 6 weeks of hospitalization, the patient’s mother confessed in writing to having performed multiple actions that resulted in different signs and symptoms. These actions ranged from (1) erroneous reporting (fever; medication not given), to (2) interference of specimens (blood in urine/diaper; manipulation of thermometer), and (3) induction of symptoms (mechanical irritation; application of capsaicin, anti-wart patches, mydriatic eye drops and saliva/stool application to induce skin infection) (Table 2).

Retrospectively, the primary care pediatrician reported abnormally frequent visits of the mother with her son to his medical practice, with up to 12 visits a month, possibly indicating secondary gain for the mother. However,
no medical opinions beyond our center were accessed by the family. At the age of 3 years, a diagnosis of MBPS was firmly established with the evidence that separating mother and child led to spontaneous resolution of all disease symptoms and signs, along with the confession from the mother.

**Review of the literature**

MBPS is a potentially life-threatening disorder with up to 6% mortality. The clinical spectrum ranges from a caregiver displaying too much concern regarding minor symptoms, to a caregiver inducing illness with possible major impact on the child’s physical and mental health [8]. Factitious disorders in adolescents and adults have been described to simulate rheumatic conditions such as panniculitis or lupus [9, 10]. Such observations have been made in patients treated for lupus-like disease who were for example positive for ANA (an unspecific finding) and also had the appearance of renal symptoms (due to manipulated urine), rash (which was fabricated) along with reported photosensitivity or arthritis [10]. Nonetheless, a search of PubMed with the terms “Munchausen Syndrome by Proxy” and “Rheumatology”, “Autoinflammation”, “Autoimmunity”, “Arthritis” or “Lupus” retrieved no results for original data.

In contrast, fever was reported as early as 1987 as belonging to one of the most frequent symptoms of MBPS detected in 10% of 117 cases along with bleeding (44%), seizures (42%), CNS depression (19%), apnoea (15%), diarrhoea (11%) and vomiting (10%) [11]. Fever in MBPS can result from the induced infections, but is also falsely reported or fabricated via the manipulation of thermometers, physically generated hyperthermia, or falsified.

**Table 2 Symptoms and probable causative action of the mother**

| Symptom                        | Probable etiology                                                                 |
|--------------------------------|-----------------------------------------------------------------------------------|
| erythematous skin lesions      | rubbing and mechanical irritation; application of capsaicin containing ointments  |
| macrohaematuria, bloody        | addition of maternal blood                                                        |
| diarrhoea and epistaxis        | manipulation of thermometer; deceptively reporting by the mother                  |
| fever episodes, documented     | extensive rubbing and mechanical irritation                                         |
| also during hospitalisation    | mechanical manipulation                                                            |
| ulcerations and excoriations   | administration of anti-warts patches                                               |
| ulcerations after vaccinations  | mechanical manipulation                                                            |
| and bone marrow puncture       | administration of mydriatic eye drops                                              |
| palmar and plantar bullous     | mechanical manipulation                                                            |
| skin lesions                   | administration of salivate or diaper content                                        |
| angioedema in face and         | mechanical manipulation; presumably application of capsaicin containing ointments |
| dorsum of hands and feet       |                                                                                  |
| anisocoria                      |                                                                                  |
| Infections of the acoustic     |                                                                                  |
| meatus                         |                                                                                  |

**Discussion and conclusions**

The mean time from the onset of symptoms to the time of diagnosis in MBPS is around 15 months [11]. Recognition of MBPS early in the disease course is difficult and, as in this case, can be delayed for several reasons. Importantly, clinical and skin biopsy findings were misinterpreted. Therefore in this case, the popular phrase coined by Maslow “if all you have is a hammer, everything looks like a nail” applies. We were, in retrospect, focussing for too long on identifying a unifying inflammatory condition for this patient’s disease process.

Even though the maternal actions (Table 2) have been identified as MVK deficiency, being mistaken as MBPS [18].

While fever is a frequent sign associated with MBPS, there are no previous reports or case series on patients with MBPS who had been mistaken as SAIDs. On the other hand, since SAIDs comprise a heterogeneous group of inflammatory disorders that were collectively defined only around 15 years ago, an under diagnosis of charts [11]. Fever in MBPS has also been chemically induced by the deliberate administration of diazoxide, alimemazine, ipecac, or mercury poisoning [12–15].

MBPS mimicking rheumatic conditions is probably uncommon but may be underreported. A case-report from 1987 describes a 7-year old girl, who presented with fever of unknown origin and then repeatedly presented with remitting fever over a period of 6 years and was transiently treated as SJIA. Additional observations were asthma, chronic purulent otitis media, and unilateral mydriasis. Finally, severe diarrhoea and vomiting found to be due to theophylline intoxication, were the last symptoms before discovery of the underlying condition [16].

We are aware of another MBPS case, which was first erroneously treated for hemophagocytic lymphohistiocytosis (HLH), another rare immunologic condition associated with recurrent fevers [17]. However, the reverse has also been reported, with a case of an SAID, later identified as MVK deficiency, being mistaken as MBPS [18].
SAIDs is also likely [1]. It remains a clinical dilemma that fever may be a sign of serious disease processes including SAIDs, but, as discussed above, can also be produced factitiously by various means. Therefore, critical evaluation and scrutiny of recurrent fevers in children is mandatory. A high index of suspicion both for SAID and MBPS is needed to unravel cases with atypical combinations of symptoms and a poor response to anti-inflammatory therapies.

In conclusion, we describe for the first time a clinical case of MBPS specifically mimicking SAIDs, which resulted in a delayed diagnosis. We recommend MBPS be added to the differential diagnosis of SAIDs. Inconsistent clinical findings, for example lack of measurable inflammation during fever, should prompt suspicion for diagnosis of MBPS.

Abbreviations
CAPS: Cryopyrin associated periodic syndrome; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; FMF: Familial Mediterranean fever; MBPS: Muenchhausen by proxy syndrome; MK: Mevalonate kinase deficiency; SAA: Serum amyloid A; SAIDs: Systemic autoinflammatory diseases; TRAPS: Tumor necrosis factor receptor associated periodic syndrome

Aknowledgments
We are grateful to all physicians and health-care workers involved in this complicated case, who finally helped to find the right diagnosis and to cure the patient. Especially we would like to thank Dr Robert A. Shapiro and Dr Kathi L. Makoroff from Mayerson Center for Safe and Healthy Children (Cincinnati Children’s Hospital, Ohio), Prof Frank U. Müller and Dr Frank Stümpel (Institute of Pharmacology and Toxicology, WWU Münster), Dr Bernd Karger (forensic medicine, University hospital Muenster), and Friedhelm Kosmann (psychosocial service, University hospital Muenster). Additionally we are grateful to Faekah Gohar (MD) for proofreading the manuscript as a native speaker.

Funding
Not applicable.

Availability of data and materials
Data are available on request due to privacy.

Authors’ contributions
HW, CH, SHH, KM, MM, VO, UG, and DF made substantial contributions to acquisition, analysis and interpretation of data; HW, CH, and DF drafted the manuscript; SHH, KM, MM, VO, and UG revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
I confirm, that written consent to publish the individual patient data for this case report was obtained from the parents of our case before submission of the manuscript.

Ethics approval and consent to participate
Not applicable.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Paediatric Rheumatology and Immunology, University Children’s Hospital Muenster, Albert-Schweitzer-Campus 1, Bld W30, D-48149 Munster, Germany. 2Department of General Pediatrics, University Children’s Hospital Muenster, Muenster, Germany. 3Department of Dermatology, University Hospital Muenster, Muenster, Germany. 4Department of Ophthalmology, University Hospital Muenster, Muenster, Germany.

Received: 6 December 2016 Accepted: 27 March 2017
Published online: 05 April 2017

References
1. Masters SL, Simon A, Akseintjevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol. 2009;27:621–68. doi:10.1146/annurev.immunol.25.022106.141627.
2. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3, e297.
3. Park H, Bourla AB, Kastner DL, et al. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol. 2012;12:570.
4. Meadow R. Munchausen syndrome by proxy. The hinterland of child abuse. Lancet. 1977;2:343.
5. Bass C, Glaser D. Early recognition and management of fabricated or induced illness in children. Lancet. 201:438:1412.
6. Stirling Jr J, American Academy of Pediatrics Committee on Child Abuse and Neglect. Beyond Munchausen syndrome by proxy: identification and treatment of child abuse in a medical setting. Pediatrics. 2007;119:1026.
7. Chistian CW, Committee on Child Abuse and Neglect, American Academy of Pediatrics. The evaluation of suspected child physical abuse. Pediatrics. 2015;135(S1):e337–54.
8. Flaherty EG, Macmillan HL. Committee On Child Abuse And Neglect. Caregiver-fabricated illness in a child: a manifestation of child maltreatment. Pediatrics. 2013;132:590.
9. Tausche AK, Hänsel S, Tausche K, Unger S, Schröder HE, Pietzsch J. Case number 31: Nodular panniculitis as expression of Munchausen’s syndrome (panniculitis artefacta). Ann Rheum Dis. 2004;63(10):1195–6.
10. Iaculco-Parra JA, Guevara-Gutierrez E, Garcia-De La Torre I. Factitious disorders mimicking systemic lupus erythematosus. Clin Exp Rheumatol. 2000;18(1):89–93.
11. Rosenberg DA. Web of deceit: a literature review of Munchausen syndrome by proxy. Child Abuse Negl. 1987;11(4):547–63.
12. Gomila I, López-Corominas V, Pellegrini M, Quesada L, Miravet E, Pichini S, Barceló B. Alimentemaine poisoning as evidence of Munchausen syndrome by proxy: a pediatric case report. Forensic Sci Int. 2016;266:e18–22.
13. Türkmên Z, Ziyalar N, Tari I, Mercan S, Kayaian SM, Sener D, Cengiz S, Akgayka N. Toxicological evaluation of two children diagnosed as Munchausen syndrome by proxy. Turk J Pediatr. 2012;54(3):283–6.
14. Ozon A, Demirkılık H, Ertugrul A, Unal S, Gumruk F, Kandemir N. Anemia and neutropenic fever with high dose diazoxide treatment in a case with Munchausen syndrome by proxy. Turk J Pediatr Endocrinol Metab. 2010;23(7):719–23.
15. Bader AA, Kerzner B. Ipecac toxicity in “Munchausen syndrome by proxy”. Ther Drug Monit. 1999;21(2):259–60.
16. Wood PR, Fowlkes J, Holden P, Casto D. Fever of unknown origin for six years: Munchausen syndrome by proxy. J Fam Pract. 1989;28(4):391–5.
17. Lehmburg K, Spethake J, Rohde H, et al. Administration of Parenteral Exogenous NOXA in Munchhausena Syndrome by Proxy Can Elicit the Full Picture of HLH. Pediatr Blood Cancer. 2016;63(12):2546.
18. Farber CM, Wanders JA, Goffard JC, Parmia J. A woman with recurrent “infections” since birth—a new mevalonate kinase mutation. Acta Clin Belg. 2011;66(2):129–31.
19. Schreier H. Munchausen by proxy defined. Pediatrics. 2002;110:985.
20. Harth W, Taube KM, Gieeler U. Factitious disorders in dermatology. J Dtsch Dermatol Ges. 2010;8(5):361–72.
21. Derlin T, Klautmann S, Habermann CR. Munchhausena syndrome presenting as fever of unknown origin: diagnosis by F-18 FDG PET/CT. Clin Nucl Med. 2011;36(12):1129–30.